{"filing":{"accession_number":"0001178253-26-000037","cik":"0001178253","ticker":"SCYX","company_name":"SCYNEXIS INC","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-25","primary_document":"scyx-20260925.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1178253/000117825326000037/scyx-20260925.htm"},"events":[{"id":35416,"run_id":32619,"accession_number":"0001178253-26-000037","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"SCYNEXIS entered into a material contract with BARDA providing up to $214 million in non-dilutive federal funding to support development of SCY-247, a second-generation antifungal candidate through NDA submission for two indications. This strategic partnership strengthens the company's pipeline, accelerates development of a Phase-2-ready program, and extends cash runway into 2029.","company_name":"SCYNEXIS INC","ticker":"SCYX","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39450,"accession_number":"0001178253-26-000037","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"SCYNEXIS entered into a material contract with BARDA providing up to $214 million in non-dilutive federal funding to support development of SCY-247, a second-generation antifungal candidate. While this is a significant strategic partnership and funding arrangement, it does not fit neatly into the specific financial categories (debt_issuance, dilutive_issuance, dividend_distribution) or other named types. The event is clearly operational and strategic in nature—a major research and development partnership with a government agency that strengthens the company's pipeline and cash position—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:03:54.044448+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39451,"accession_number":"0001178253-26-000037","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"SCYNEXIS announced a BARDA contract award providing up to $214 million in non-dilutive funding to advance SCY-247 development through NDA submission for two indications. This is a material operational and strategic milestone—a significant government partnership that strengthens the company's pipeline, accelerates development of a Phase-2-ready program, and extends cash runway into 2029. While the funding is substantial, it does not constitute a debt issuance (no direct financial obligation created), M\u0026A activity, or other specifically-named event types; rather, it is a material strategic partnership and funding arrangement that clearly affects the registrant's operational prospects and investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:03:54.044448+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39450,"accession_number":"0001178253-26-000037","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"SCYNEXIS entered into a material contract with BARDA providing up to $214 million in non-dilutive federal funding to support development of SCY-247, a second-generation antifungal candidate. While this is a significant strategic partnership and funding arrangement, it does not fit neatly into the specific financial categories (debt_issuance, dilutive_issuance, dividend_distribution) or other named types. The event is clearly operational and strategic in nature—a major research and development partnership with a government agency that strengthens the company's pipeline and cash position—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:03:54.044448+00:00","company_name":"SCYNEXIS INC","ticker":"SCYX","filing_date":"2026-09-28"},{"id":39451,"accession_number":"0001178253-26-000037","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"SCYNEXIS announced a BARDA contract award providing up to $214 million in non-dilutive funding to advance SCY-247 development through NDA submission for two indications. This is a material operational and strategic milestone—a significant government partnership that strengthens the company's pipeline, accelerates development of a Phase-2-ready program, and extends cash runway into 2029. While the funding is substantial, it does not constitute a debt issuance (no direct financial obligation created), M\u0026A activity, or other specifically-named event types; rather, it is a material strategic partnership and funding arrangement that clearly affects the registrant's operational prospects and investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:03:54.044448+00:00","company_name":"SCYNEXIS INC","ticker":"SCYX","filing_date":"2026-09-28"}]}